For example, a study showed that there were tumor-associated mutations for HCC in only 8 of 41 patient (19.5%) plasma samples, including mutation to such genes as TP53, hTERT, and CTNNB1 (Liao et al., 2016). This evidence concerns the gene TP53 and neoplasm.